Bolt Biotherapeutics, Inc. 6LP.F Stock
Bolt Biotherapeutics, Inc. Price Chart
Bolt Biotherapeutics, Inc. 6LP.F Financial and Trading Overview
| Bolt Biotherapeutics, Inc. stock price | 1.16 EUR |
| Previous Close | 1.37 EUR |
| Open | 1.35 EUR |
| Bid | 1.4 EUR x N/A |
| Ask | 1.46 EUR x N/A |
| Day's Range | 1.35 - 1.35 EUR |
| 52 Week Range | 1.14 - 2.52 EUR |
| Volume | 450 EUR |
| Avg. Volume | 340 EUR |
| Market Cap | 51.42M EUR |
| Beta (5Y Monthly) | 1.019105 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.71 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 40.8 EUR |
6LP.F Valuation Measures
| Enterprise Value | -47531400 EUR |
| Trailing P/E | N/A |
| Forward P/E | -0.49632353 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 7.626879 |
| Price/Book (mrq) | 0.32374102 |
| Enterprise Value/Revenue | -7.05 |
| Enterprise Value/EBITDA | 0.572 |
Trading Information
Bolt Biotherapeutics, Inc. Stock Price History
| Beta (5Y Monthly) | 1.019105 |
| 52-Week Change | -12.73% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 2.52 EUR |
| 52 Week Low | 1.14 EUR |
| 50-Day Moving Average | 1.45 EUR |
| 200-Day Moving Average | 1.43 EUR |
6LP.F Share Statistics
| Avg. Volume (3 month) | 340 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 37.81M |
| Float | 20.07M |
| Short Ratio | N/A |
| % Held by Insiders | 6.52% |
| % Held by Institutions | 57.39% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -1258.67% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -21.69% |
| Return on Equity (ttm) | -42.16% |
Income Statement
| Revenue (ttm) | 6.74M EUR |
| Revenue Per Share (ttm) | 0.18 EUR |
| Quarterly Revenue Growth (yoy) | 124.59% |
| Gross Profit (ttm) | 1.62M EUR |
| EBITDA | -83084000 EUR |
| Net Income Avi to Common (ttm) | -81400000 EUR |
| Diluted EPS (ttm) | -2.12 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 126.38M EUR |
| Total Cash Per Share (mrq) | 3.34 EUR |
| Total Debt (mrq) | 22.05M EUR |
| Total Debt/Equity (mrq) | 13.99 EUR |
| Current Ratio (mrq) | 8.098 |
| Book Value Per Share (mrq) | 4.17 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -75589000 EUR |
| Levered Free Cash Flow (ttm) | -46998500 EUR |
Profile of Bolt Biotherapeutics, Inc.
| Country | Germany |
| State | CA |
| City | Redwood City |
| Address | 900 Chesapeake Drive |
| ZIP | 94063 |
| Phone | 650 665 9295 |
| Website | https://www.boltbio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 94 |
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in Phase II clinical trial for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-2034, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
Q&A For Bolt Biotherapeutics, Inc. Stock
What is a current 6LP.F stock price?
Bolt Biotherapeutics, Inc. 6LP.F stock price today per share is 1.16 EUR.
How to purchase Bolt Biotherapeutics, Inc. stock?
You can buy 6LP.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Bolt Biotherapeutics, Inc.?
The stock symbol or ticker of Bolt Biotherapeutics, Inc. is 6LP.F.
Which industry does the Bolt Biotherapeutics, Inc. company belong to?
The Bolt Biotherapeutics, Inc. industry is Biotechnology.
How many shares does Bolt Biotherapeutics, Inc. have in circulation?
The max supply of Bolt Biotherapeutics, Inc. shares is 38.13M.
What is Bolt Biotherapeutics, Inc. Price to Earnings Ratio (PE Ratio)?
Bolt Biotherapeutics, Inc. PE Ratio is now.
What was Bolt Biotherapeutics, Inc. earnings per share over the trailing 12 months (TTM)?
Bolt Biotherapeutics, Inc. EPS is -1.71 EUR over the trailing 12 months.
Which sector does the Bolt Biotherapeutics, Inc. company belong to?
The Bolt Biotherapeutics, Inc. sector is Healthcare.